SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Ronkainen Antti)) srt2:(2020-2024)
 

Search: (WFRF:(Ronkainen Antti)) srt2:(2020-2024) > (2024) > Prostate Cancer Scr...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Auvinen, AnssiUniversity of Tampere (author)

Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI : The ProScreen Randomized Trial

  • Article/chapterEnglish2024

Publisher, publication year, extent ...

  • 2024

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:0e2ba345-33d7-43c7-b392-9a99376dd7e4
  • https://lup.lub.lu.se/record/0e2ba345-33d7-43c7-b392-9a99376dd7e4URI
  • https://doi.org/10.1001/jama.2024.3841DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • IMPORTANCE: Prostate-specific antigen (PSA) screening has potential to reduce prostate cancer mortality but frequently detects prostate cancer that is not clinically important.OBJECTIVE: To describe rates of low-grade (grade group 1) and high-grade (grade groups 2-5) prostate cancer identified among men invited to participate in a prostate cancer screening protocol consisting of a PSA test, a 4-kallikrein panel, and a magnetic resonance imaging (MRI) scan.DESIGN, SETTING, AND PARTICIPANTS: The ProScreen trial is a clinical trial conducted in Helsinki and Tampere, Finland, that randomized 61 193 men aged 50 through 63 years who were free of prostate cancer in a 1:3 ratio to either be invited or not be invited to undergo screening for prostate cancer between February 2018 and July 2020.INTERVENTIONS: Participating men randomized to the intervention underwent PSA testing. Those with a PSA level of 3.0 ng/mL or higher underwent additional testing for high-grade prostate cancer with a 4-kallikrein panel risk score. Those with a kallikrein panel score of 7.5% or higher underwent an MRI of the prostate gland, followed by targeted biopsies for those with abnormal prostate gland MRI findings. Final data collection occurred through June 31, 2023.MAIN OUTCOMES AND MEASURES: In descriptive exploratory analyses, the cumulative incidence of low-grade and high-grade prostate cancer after the first screening round were compared between the group invited to undergo prostate cancer screening and the control group.RESULTS: Of 60 745 eligible men (mean [SD] age, 57.2 [4.0] years), 15 201 were randomized to be invited and 45 544 were randomized not to be invited to undergo prostate cancer screening. Of 15 201 eligible males invited to undergo screening, 7744 (51%) participated. Among them, 32 low-grade prostate cancers (cumulative incidence, 0.41%) and 128 high-grade prostate cancers (cumulative incidence, 1.65%) were detected, with 1 cancer grade group result missing. Among the 7457 invited men (49%) who refused participation, 7 low-grade prostate cancers (cumulative incidence, 0.1%) and 44 high-grade prostate cancers (cumulative incidence, 0.6%) were detected, with 7 cancer grade groups missing. For the entire invited screening group, 39 low-grade prostate cancers (cumulative incidence, 0.26%) and 172 high-grade prostate cancers (cumulative incidence, 1.13%) were detected. During a median follow-up of 3.2 years, in the group not invited to undergo screening, 65 low-grade prostate cancers (cumulative incidence, 0.14%) and 282 high-grade prostate cancers (cumulative incidence, 0.62%) were detected. The risk difference for the entire group randomized to the screening invitation vs the control group was 0.11% (95% CI, 0.03%-0.20%) for low-grade and 0.51% (95% CI, 0.33%-0.70%) for high-grade cancer.CONCLUSIONS AND RELEVANCE: In this preliminary descriptive report from an ongoing randomized clinical trial, 1 additional high-grade cancer per 196 men and 1 low-grade cancer per 909 men were detected among those randomized to be invited to undergo a single prostate cancer screening intervention compared with those not invited to undergo screening. These preliminary findings from a single round of screening should be interpreted cautiously, pending results of the study's primary mortality outcome.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03423303.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Tammela, Teuvo L JUniversity of Tampere (author)
  • Mirtti, TuomasHelsinki University Central Hospital (author)
  • Lilja, HansLund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Clinical Chemistry, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Memorial Sloan-Kettering Cancer Center(Swepub:lu)klke-hli (author)
  • Tolonen, TeemuUniversity of Tampere (author)
  • Kenttämies, AnuHelsinki University Central Hospital (author)
  • Rinta-Kiikka, IrinaUniversity of Tampere (author)
  • Lehtimäki, TerhoUniversity of Tampere (author)
  • Natunen, KariUniversity of Tampere (author)
  • Nevalainen, JaakkoUniversity of Tampere (author)
  • Raitanen, JaniUniversity of Tampere (author)
  • Ronkainen, JohannaTampere University Hospital (author)
  • van der Kwast, TheodorusUniversity of Toronto (author)
  • Riikonen, JarnoTampere University Hospital (author)
  • Pétas, AnssiHelsinki University Central Hospital (author)
  • Matikainen, MikaHelsinki University Central Hospital (author)
  • Taari, KimmoUniversity of Helsinki (author)
  • Kilpeläinen, TuomasUniversity of Helsinki (author)
  • Rannikko, Antti SUniversity of Helsinki (author)
  • University of TampereHelsinki University Central Hospital (creator_code:org_t)
  • ProScreen Trial Investigators

Related titles

  • In:JAMA331:17, s. 1452-14590098-7484

Internet link

Find in a library

  • JAMA (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view